Comprehensive analysis of glycometabolism-related genes reveals PLOD2 as a prognostic biomarker and therapeutic target in gastric cancer
This study identifies PLOD2 as a key prognostic biomarker and therapeutic target in gastric cancer. As a central component in a glycometabolism-related model, PLOD2 promotes glycolysis, tumor progression, and immune evasion via the PI3K/AKT/mTOR pathway. The model effectively stratifies patient risk, offering both prognostic utility and therapeutic insight. Targeting PLOD2-mediated pathways may represent a promising strategy for precision therapy and improved clinical outcomes in gastric cancer.
Authors
- Wanchun Ye
- Yuanliang Zheng
- Zhongjie Tang (ORCID: https://orcid.org/0000-0002-0543-6896)
- Yuping Yuan
- Yufeng Hu (ORCID: https://orcid.org/0000-0002-8226-2156)
- Xiaolei Zhang (ORCID: https://orcid.org/0009-0005-9473-0091)
Institutions
- Wenzhou Medical University (CN)
- Fourth People’s Hospital of Jinan (CN)
Publication Details
- Journal
- BMC Gastroenterology
- Published
- 2025-04-14
- DOI
- https://doi.org/10.1186/s12876-025-03878-z
- Citations
- 1
- Primary Topic
- Cancer, Hypoxia, and Metabolism
- Type
- article
- Field-Weighted Citation Impact
- 0.94